胰腺癌的液态活检 - 当前视角及未来展望。
Liquid biopsy in pancreatic cancer - Current perspective and future outlook.
发表日期：2023 Feb 24
作者：
Yaru Zhao, Jiajia Tang, Ke Jiang, Shin-Yi Liu, Alexandra Aicher, Christopher Heeschen
来源：
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
摘要：
胰腺癌是一种致命的疾病，发病率呈上升趋势，常常出现在晚期，导致五年生存率极低。非特异性症状以及目前缺乏生物标志物和筛查工具阻碍了早期诊断。近年来液体活检技术及其在胰腺癌患者中的评估逐渐出现。液体活检一词汇总了使用微创程序从体液中采样和分析循环肿瘤细胞（CTCs）、小型细胞外囊泡（sEVs）和肿瘤DNA（ctDNA）的过程。液体活检的主要优点在于其微创性和可重复性，允许动态检查以协助确诊，特别是在胰腺癌的早期检测、风险分层和精准医学中。然而，液体活检还未发展成为临床医生常规工具的新支柱。本文总结了液体活检在胰腺癌患者中的最新研究进展，讨论了当前的挑战和未来的前景，探讨了作为传统组织活检替代品的潜在强大优势。版权所有© 2023 Elsevier B.V.出版。
Pancreatic cancer is a lethal condition with a rising incidence and often presents at an advanced stage, contributing to abysmal five-year survival rates. Unspecific symptoms and the current lack of biomarkers and screening tools hamper early diagnosis. New technologies for liquid biopsies and their respective evaluation in pancreatic cancer patients have emerged over recent years. The term liquid biopsy summarizes the sampling and analysis of circulating tumor cells (CTCs), small extracellular vesicles (sEVs), and tumor DNA (ctDNA) from body fluids using minimally invasive procedures. The major advantages of liquid biopsies rely on their minimal invasiveness and repeatability, allowing serial sampling for dynamic insights to aid diagnosis, particularly early detection, risk stratification, and precision medicine in pancreatic cancer. However, liquid biopsies have not yet developed into a new pillar for clinicians' routine armamentarium. Here, we summarize recent findings on the use of liquid biopsy in pancreatic cancer patients. We discuss current challenges and future perspectives of this potentially powerful alternative to conventional tissue biopsies.Copyright © 2023. Published by Elsevier B.V.